Top 75 medical and healthcare startups in France
Nov 30, 2025
|
Like
16
1
Funding: €135M
Adcytherix is dedicated to creating and advancing innovative antibody-drug conjugates (ADCs) that go beyond current limitations. By combining state-of-the-art payload innovation with deep ADC development expertise, the company aims to revolutionize targeted therapies for cancer and other conditions of significant unmet medical need. Most existing ADCs rely on two classes of payloads, tubulin and topoisomerase 1 inhibitors. Adcytherix is investigating novel payloads classes with mechanisms of action selected to overcome tumor resistance while enhancing safety, with the potential to manage a wider range of cancers. Adcytherix is guided by a experienced management team and is backed by a network of top-tier experts in the field of ADC development.
Adcytherix is dedicated to creating and advancing innovative antibody-drug conjugates (ADCs) that go beyond current limitations. By combining state-of-the-art payload innovation with deep ADC development expertise, the company aims to revolutionize targeted therapies for cancer and other conditions of significant unmet medical need. Most existing ADCs rely on two classes of payloads, tubulin and topoisomerase 1 inhibitors. Adcytherix is investigating novel payloads classes with mechanisms of action selected to overcome tumor resistance while enhancing safety, with the potential to manage a wider range of cancers. Adcytherix is guided by a experienced management team and is backed by a network of top-tier experts in the field of ADC development.
2
Funding: $1.1B
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
3
Funding: $816.5M
Doctolib is an online and mobile booking platform that helps to find a specialist doctor nearby and make an appointment.
Doctolib is an online and mobile booking platform that helps to find a specialist doctor nearby and make an appointment.
4
Funding: €666M
Alan wants to make health insurance as simple as subscribing to a software-as-a-service product. It starts with clear pricing and transparent reimbursement policies.
Alan wants to make health insurance as simple as subscribing to a software-as-a-service product. It starts with clear pricing and transparent reimbursement policies.
5
Funding: $393.5M
Cellectis has developed genome editing technology TALEN, which enables it to create more affordable, ready-to-use allogeneic CAR T-cell therapies. Its technology offers protection against graft-versus-host disease, reduces the risk of rejection and improves safety by integrating a self-destruct mechanism. Using this technology, the company is developing a pipeline of several candidates against non-Hodgkin's lymphoma, large B-cell lymphoma, renal cell carcinoma and melanoma. Cellectis is also advancing PulseAgile technology, which uses electroporation (controlled electric fields) to deliver messenger RNA molecules into cells. It utilizes a unique electric field waveform, which, combined with a proprietary buffer solution, allows molecules such as nucleases to effectively penetrate cells while maintaining high cell viability.
Cellectis has developed genome editing technology TALEN, which enables it to create more affordable, ready-to-use allogeneic CAR T-cell therapies. Its technology offers protection against graft-versus-host disease, reduces the risk of rejection and improves safety by integrating a self-destruct mechanism. Using this technology, the company is developing a pipeline of several candidates against non-Hodgkin's lymphoma, large B-cell lymphoma, renal cell carcinoma and melanoma. Cellectis is also advancing PulseAgile technology, which uses electroporation (controlled electric fields) to deliver messenger RNA molecules into cells. It utilizes a unique electric field waveform, which, combined with a proprietary buffer solution, allows molecules such as nucleases to effectively penetrate cells while maintaining high cell viability.
6
Funding: $315.9M
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
7
Funding: $304.1M
OWKIN is the AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes.
OWKIN is the AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes.
8
Funding: $277.5M
Genfit SA, a biopharmaceutical engages in the research and development of drugs for the prevention and treatment.
Genfit SA, a biopharmaceutical engages in the research and development of drugs for the prevention and treatment.
9
Funding: €258.1M
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
10
Funding: $274.4M
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
11
Funding: $219.7M
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
12
Funding: $210M
Tissium invents the next generation of synthetic polymers for tissue reconstruction
Tissium invents the next generation of synthetic polymers for tissue reconstruction
13
Funding: €193.1M
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
14
Funding: $179.5M
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
15
Funding: $170.6M
Wandercraft develops and sells the first exoskeleton to walk self-balanced, for inpatient rehab and outpatient daily life.
Wandercraft develops and sells the first exoskeleton to walk self-balanced, for inpatient rehab and outpatient daily life.
16
Funding: €132.3M
Diabeloop is a medical device company for diabetes and closed-loop system.
Diabeloop is a medical device company for diabetes and closed-loop system.
17
Funding: $127.6M
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
20
Funding: $114.7M
Nabla is the developer of Nabla Copilot, an ambient AI that helps clinicians enjoy care again.
Nabla is the developer of Nabla Copilot, an ambient AI that helps clinicians enjoy care again.
